Table 3 Individual characteristics and treatment outcomes for RN patients
Study | Age | Sex | Primary histology | Radiation | Dose | RN site | Last RT to RN diagnosis | RT to BV Tx | BV dosage (mg/kg) | No of treatments | Treatment Duration (months) | Volume reduction on T1W-Gd-enhanced MRI | Volume reduction on T2W FLAIR MRI | Pre-Tx KPS | Post-Tx KPS | KPS increase | Pre-Tx Dex (mg) | Post-Tx Dex (mg) | Dex reduction (mg) | Presenting Symptoms | Improvement | Adverse events |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Wang, et al. (2012) [50] | 70 | M | colon | SRS | 17 Gy | L temporal | 6 | 0 | 0 | 30 | 30 | 0 | 15 | 12.5 | 2.5 | Improved | ||||||
71 | M | colon | EBRT | 36 Gy | L frontal | 4 | 65 | 10 | 40 | 80 | 40 | 15 | 5 | 10 | Improved | |||||||
71 | M | Lung | FSRT | 31.5 Gy/3f | L occipital | 7 | 87 | 78 | 50 | 90 | 40 | 15 | 0 | 15 | Improved | |||||||
67 | F | colon | EBRT SRS | 39 Gy/10 f 16 Gy | R frontal | 1 | 52 | 78 | 50 | 90 | 40 | 15 | 0 | 15 | Worsened | |||||||
46 | M | Lung | EBRT SRS | 30 Gy/13 f 16 Gy | L occipital | 5 | 50 | 30 | 60 | 80 | 20 | 12.5 | 5 | 7.5 | Improved | |||||||
Boothe, et al. (2013) [51] | 58 | M | NSCLC | WBRT SRS | 37.5 25/25 | R frontal/L temporal | 10q2w | 2.3 | 38/64 | 3/36 | 8 | 0 | 8 | None | Improved | |||||||
50 | F | Breast | SRS | 30 | R occipital | 10q2w | 2.3 | 82 | 75 | 2 | 0.3 | 1.7 | Visual field disturbance, headaches | Stable | ||||||||
27 | F | Breast | WBRT SRS | 37.5 18/21/21 | L frontal/L temporal/R parietal | 10q2w | 1.4 | 38/64/91 | 70/67/63.5 | 4 | 0 | 4 | Seizures | Improved | ||||||||
79 | F | NSCLC | SRS | 18 | R parietal | 10q2w | 0.5 | 82 | 60 | 0.2 | 0 | 0.2 | Lower left leg weakness | Improved | ||||||||
67 | F | Breast | WBRT SRS | 30 18 | Cerebellum | 10q2w | 14.3 | 73 | 72 | Headaches, lower leg weakness | Stable | |||||||||||
54 | F | Breast | WBRT SRS | 37.5 15 | R frontal | 10q2w | 3.9 | 21 | 44.6 | Left arm weakness | Improved | |||||||||||
67 | M | NSCLC | SRS | 30 | R frontal | 15q6w | 2.8 | 10 | 3 | 24 | 0 | 24 | Seizures, left sided weakness | Improved | ||||||||
50 | F | Breast | WBRT SRS | 35 21 | R frontal | 7.5q3w | 1.4 | 91 | 46 | 20 | 0 | 20 | Fatigue, lethargy, facial asymmetry | Improved | ||||||||
67 | F | NSCLC | SRS | 21 | L occipital | 102w 4 w | 89 | 84.5 | 6 | 0 | 6 | Confusions, visual hallucinations | Stable | |||||||||
73 | M | NSCLC | SRS | 21 | L parietal | 102w | 96 | 54.6 | 8 | 2 | 6 | Seizure, right sided hemiparesis | Improved | |||||||||
63 | M | NSCLC | SRS | 21 | L occipital | 15q4w | 1.8 | 100 | 77 | 8 | 0 | 8 | Imbalance, right sided tinnitis | Resolved | ||||||||
Furuse, et al. (2013) [52] | 57 | F | unknown | SRS | frontal | 5 | 73.4 | 40 | 60 | 20 | Improved | |||||||||||
74 | F | unknown | SRS | frontal | 47 | 74.4 | 60 | 60 | 0 | Resolved | ||||||||||||
55 | M | unknown | SRS | frontal | 49 | 77.5 | 80 | 90 | 10 | Stable | ||||||||||||
Yonezawa, et al. (2014) [53] | 54 | M | Lung | WBRT SRS | 30 20 | 15 | 55.9 | 88.9 | 60 | 70 | 10 | Seizure, motor weakness | Improved | |||||||||
51 | F | Lung | SRT | 30/5 f | 23 | 43.2 | 65 | 90 | 100 | 10 | Headache, numbness | Improved | ||||||||||
Sadraei, et al. (2015) [54] | 61 | M | NSCLC | SRS | 18 Gy | R posterofrontal cingulate | 8 | 5q2w | 8 | 35.2 | 92 | 24 | 0.5 | 23.5 | Left sided weakness, gait problems | Improved | ||||||
46 | F | NSCLC | RT SRS | 36.5 24 | R cerebellar | 17 11 | 5q2w | 9 | 56.1 | 83.6 | Y | Improved | ||||||||||
62 | M | NSCLC | SRS | 18, 24, 24 | Frontal, L temporal | 16 4 | 7.5q3w | 3 | + 37.8 | + 74.1 | 16 | 4 | 12 | Y | Improved | |||||||
59 | F | NSCLC | WBRT SRS | 44 24 | R cerebellar | 6 5 | 30.8 | 58.9 | Y | Resolved | Proteinuria (bevacizumab held) grade 1 | |||||||||||
58 | F | NSCLC | WBRT SRS | 40 24 | R temporal L frontoparietal | 58 53 | 10q2w | 9 | 28.8 | 34.1 | 16 | 0 | 16 | Y | Resolved | UTI (requiring holding of 1 treatment) grade 2 | ||||||
46 | F | NSCLC | WBRT SRS | 37.5 18 | L occipital | 17 10 | 7.5q3w | 10 | 18.5 | 48.2 | 8 | 0 | 8 | Y | Improved | |||||||
58 | M | NSCLC | WBRT SRS | 37.5 24 | L parietal | 11 9 | 15q3w | 4 | 100 | 38.1 | 8 | 0 | 8 | Y | Improved | |||||||
63 | F | NSCLC | SRS | 18 | Bithalamic L midbrain | 18 | 7.5q3w | 4 | 76.9 | 52.9 | 8 | 0 | 8 | Y | No | |||||||
55 | F | Breast | WBRT SRS | 37.5 24 | L posterofrontal | 14 6 | 10q2w | 5 | 35.4 | 43.2 | 24 | 2 | 22 | Y | Improved | |||||||
58 | F | Breast | WBRT SRS | 37.5 18 | R frontal | 27 11 | 5q2w | 3 | 64.7 | 26.7 | 8 | 8 | 0 | Y | Improved | |||||||
52 | F | Breast | WBRT SRS | 37.5 18 | L cerebellar | 7 5 | 10q2w | 13 | 66.7 | 32.8 | 2 | 1 | 1 | Y | Improved | |||||||
58 | F | Melanoma | WBRT SRS | 37.5 24 | L frontal | 3 7 | 7.5q3w | 2 | 82.4 | 74.9 | 6 | 4 | 2 | Y | Resolved | DVT and PE grade 3 | ||||||
39 | F | Breast | WBRT SRS | 37.5 24 | L cerebellar | 14 8 | 10q2w | 7 | 25 | 77.3 | 8 | 0 | 8 | Y | Improved | fatigue grade 2 | ||||||
57 | F | Fallopian tube | SRS | 20 | L parietal | 6 | 15q3w | 9 | 74.5 | 84.9 | 8 | 0 | 8 | Y | Resolved | |||||||
63 | M | Rectal | WBRT SRS | 37.5 16 | L frontal | 12 4 | 10q2w | 8 | 25.4 | 13.5 | 4 | 2 | 2 | Y | Resolved | |||||||
67 | F | NSCLC | SRS | 18 | L frontal | 3 | 10q2w | 8 | 22 | 53 | 4 | 0 | 4 | Y | Resolved | |||||||
45 | M | NSTC | SRS | 18 | R frontal | 5 | 5q2w | 4 | 32.2 | 46.2 | 4 | 0 | 4 | Y | Resolved | Hypertension grade 2 | ||||||
Xiang-Pan, L., et al. (2015) [49] | 60 | F | lung | WBRT SRS | L temporal | 12 | 7.5q3w | ⇓ | ⇓ | Resolved | ||||||||||||
Alessandretti, et al. (2013) [48] | 51 | F | melanoma | WBRT SRS (3 lesions) | 17 | 5q2w/ 7.5q4w | 3 | ⇓ | ⇓ | 4 | 0 | 4 | severe drowsiness, unable to self-ambulate | Resolved | ||||||||
48 | F | melanoma | SRS WBRT | 6 | 5q6w | ⇓ | ⇓ | 4 | 0 | 4 | partial seizures (facial tremor) | Resolved | ||||||||||
Tanigawa, et al. (2019) [56] | 78 | M | Lung (adenocarcinoma) | STI (stereotactic irradiation) | 9.2 | 15q3–4w | ⇓ | ⇓ | Y | Resolved | Hypertension, proteinuria | |||||||||||
74 | M | Lung (adenocarcinoma) | STI (stereotactic irradiation) | 12.2 | 15q3–4w | ⇓ | ⇓ | Y | Resolved | Hypertension | ||||||||||||
49 | F | Lung (adenocarcinoma) | STI (stereotactic irradiation) | 5 | 15q3–4w | ⇓ | ⇓ | Y | Resolved | Oedema, hypertension, proteinuria | ||||||||||||
44 | F | Lung (adenocarcinoma) | STI (stereotactic irradiation) | 4.6 | 15q3–4w | ⇓ | ⇓ | Y | Resolved | proteinuria | ||||||||||||
Ma, Y., et al. (2017) [57] | 58 | F | NSCLC | SRS | 11 | 5 mg/kg q2w | 4 weeks | ⇓ | ⇓ | speech disorder and weakness in the right arm | Improved | |||||||||||
66 | F | NSCLC | SRS | 2 | 7.5 mg/kg q3w | ⇓ | ⇓ | headache and fatigue | resolved | |||||||||||||
Glitza, I. et al. (2017) [58] | 56 | M | Melanoma | WB SRS | 30 18 | L frontal | 4 | 7.5 | 4 | ⇓ | ⇓ | Memory loss, seizure | Improvement | |||||||||
71 | F | Melanoma | SRS | 20 | R frontal | 13 | 7.5 | 3 | ⇓ | ⇓ | Seizures, expressive aphrasia | Improvement | ||||||||||
64 | F | Melanoma | WB | 30 | R parietal | 4 | 7.5 | 5 | ⇓ | ⇓ | Weakness, gait disturbance, aphasia, memory loss | Resolution | Arthralgia, dysgeusia | |||||||||
52 | M | Melanoma | SRS WB | 20/12/18 30 | R frontal | 13 | 5 | 2 | Weakness, gait disturbance, cognitive deficit | worsened | ||||||||||||
65 | M | Melanoma | SRS | 20/16 | L temporal | 8 | 7.5 | 2 | None | worsened | ||||||||||||
37 | M | Melanoma | WB | 30 | Bifrontal | 8 | 10 | 6 | ⇓ | ⇓ | Behavioral changes, memory loss | improvement | ||||||||||
55 | M | Melanoma | SRS | 24/21 | R occipital/R frontal | 7 | 7.5 | 4 | ⇓ | ⇓ | Seizure, memory loss | Improvement | ||||||||||
58 +/−10.6 | M 22, F 32 | 11.7 | 15.5 | 5.7 | 3.29 | 57.4% | 56.2% | 56 | 75 | 23.75 | 10.4 | 1.6 | 9.08 |